Rosaceiform eruption induced by cetuximab

Fernández-Torres, Rose; Gómez, Walter Martínez; Santos, Jesús Cuevas; Paradela, Sabela; Fonseca, Eduardo

doi:10.1684/ejd.2010.0900

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It comprises papules and pustules resting on an erythematous and telangiectatic base (Fig. 5) [4,9,15]. When the pustules are combined with small greasy scales, the clinical appearance resembles seborrhoeic dermatitis [4,9].…”

Section: Introductionmentioning

confidence: 99%

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

Peuvrel

Bachmeyer

Réguiai

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

Peuvrel

Bachmeyer

Réguiai

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Описан и розацеаподобный вариант акнеподобной сыпи, в клинической картине которого преобладают папулы и пустулы на эритематозном и телеангиоэктатическом фоне [4,9,13,14]. Когда пустулы сочетаются с умеренной себореей и шелушением, клиническая картина напоминает себорейный дерматит [4,9].…”

Section: специфика клинических проявлений акнеподобной сыпиunclassified

“…Тяжесть акнеподобной сыпи зависит от дозы ингибитора EGFR [1,5,7,12,14] и коррелирует с лучшим ответом на терапию при различных видах опухолей [1,5,[14][15][16][17][18][19][20]. Несмотря на то что более чем у 80 % пациентов развиваются кожные токсические реакции умеренной тяжести (I-II степени), не влияющие на летальность [4,7,9,12,21], акнеподобная сыпь из-за своей локализации (открытые участки тела), а также симптомов (зуд, болезненность) ухудшает качество жизни и может снизить приверженность к терапии [2][3][4]7].…”

Section: специфика клинических проявлений акнеподобной сыпиunclassified

Acneiform rash — skin toxic reaction to the use of EGFR inhibitors

Шатохина

Круглова

2019

Opuholi golovy i šei

View full text Add to dashboard Cite

Introduction.Inhibitors of the epidermal growth factor receptor cause the heavy dermatological adverse events, which can be the cause of change of the scheme of treatment. Acneiform rash is connected with specific inflammation of hair follicles, its weight depends on a dose of medicine and correlates with the best response to therapy at various options of tumors, in this regard effective correction of this side effect is of particular importance.Materials and methods. There were 32 patients with acneiform rash for observation; they have been divided into 3 groups. All patients received system antibacterial therapy: doxycycline 100 mg 2 times a day 10 days and topical medicines for external therapy, various on the action mechanism (tacrolimus, metronidazole, betamethasone valerate in a combination with fusidic acid). Acne Dermatology Index and Dermatology Life Quality Index were used for assessment. The received results were assesed on each visit of the patient, the final point of observations was in 3 months.Results.The significant regression of rash in all groups was in the 1st week when patients accepted doxycycline per os. Further the weakest response to therapy has shown cream with tacrolimus, the patients using gel with metronidazole has shown bigger effect, the fastest regress of Acne Dermatology Index and Dermatology Life Quality Index was observed in the patients used the combined cream with betamethasone and fusidic acid.Conclusions.The antibacterial therapy by doxycycline 100 mg 2 times a day per os at early stages of development of acneiform rash at the I—II severity gives the expressed effect and prevents deterioration of the .skin process. The combined therapy of acneiform rash of the I—II degree including doxycycline with topical cream containing a betamethasone valerate 0.1 % and fusidic acid 20 % renders the fastest and expressed effect in comparison with other combinations: the doxycycline and cream containing tacrolimus; the doxycycline and gel containing metronidazole.

show abstract

“…Despite the improved systemic tolerability towards chemotherapeutic agents, they are nevertheless associated with adverse cutaneous reactions. If not managed appropriately, these reactions can become uncomfortable and disfiguring . Although not life threatening, they are becoming an increasingly important preoccupation for both patients and their treating physicians as patient survival rates improve.…”

Section: Introductionmentioning

confidence: 99%

“…If not managed appropriately, these reactions can become uncomfortable and disfiguring. [5][6][7][8][9][10][11][12] Although not life threatening, they are becoming an increasingly important preoccupation for both patients and their treating physicians as patient survival rates improve. Skin, ocular, nail and hair toxicity have been comprehensively described in the literature as common side-effects to expect.…”

Section: Introductionmentioning

confidence: 99%

Algorithm for dermocosmetic use in the management of cutaneous side‐effects associated with targeted therapy in oncology

Dréno¹,

Bensadoun

Humbert

et al. 2013

Acad Dermatol Venereol

View full text Add to dashboard Cite

Currently, numerous patients who receive targeted chemotherapy for cancer suffer from disabling skin reactions due to cutaneous toxicity, which is a significant problem for an increasing number of patients and their treating physicians. In addition, using inappropriate personal hygiene products often worsens these otherwise manageable side-effects. Cosmetic products for personal hygiene and lesion camouflage are part of a patients’ well-being and an increasing number of physicians feel that they do not have adequate information to provide effective advice on concomitant cosmetic therapy. Although ample information is available in the literature on pharmaceutical treatment for cutaneous side-effects of chemotherapy, little is available for the concomitant use of dermatological skin-care products with medical treatments. The objective of this consensus study is to provide an algorithm for the appropriate use of dermatological cosmetics in the management of cutaneous toxicities associated with targeted chemotherapy such as epidermal growth factor receptor inhibitors and other monoclonal antibodies. These guidelines were developed by a French and German expert group of dermatologists and an oncologist for oncologists and primary care physicians who manage oncology patients. The information in this report is based on published data and the expert group’s opinion. Due to the current lack of clinical evidence, only a review of published recommendations including suggestions for concomitant cosmetic use was conducted.

show abstract

Rosaceiform eruption induced by cetuximab

Cited by 4 publications

References 0 publications

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

Acneiform rash — skin toxic reaction to the use of EGFR inhibitors

Algorithm for dermocosmetic use in the management of cutaneous side‐effects associated with targeted therapy in oncology

Contact Info

Product

Resources

About